Drug intelligence / Profile preview

zx-7101

Development stage: Unknown
Lead developer: Zenshine Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

ZX-7101 is the active metabolite of ZX-7101A, a novel small molecule antiviral developed as a **cap-dependent endonuclease inhibitor** for the treatment of influenza A and B infections. ZX-7101A is an oral prodrug rapidly converted in vivo to ZX-7101, which inhibits the polymerase acidic (PA) protein of the influenza virus, blocking viral mRNA synthesis. Clinical data show that single oral doses of 40 or 80 mg are effective and well tolerated in uncomplicated influenza, and development includes both tablet and oral suspension formulations for adult and pediatric populations[1][2][3][4][5].

Other names: 玛赛洛沙韦

Targets

CEN (Influenza A virus (2009 H1N1) polymerase acidic protein (PA) endonuclease)

Beyond the preview

Go deeper on zx-7101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on zx-7101.

Explore the full profile